BACKGROUND: Procalcitonin is involved in the inflammatory response and is associated with adverse prognosis in certain conditions. AIMS: To investigate the association between procalcitonin and major adverse cardiac events (MACE), left ventricular (LV) function and remodelling following acute myocardial infarction (AMI). METHODS: Plasma procalcitonin was measured in 977 patients with AMI. Subjects were followed for MACE (median 671 days). A subgroup underwent echocardiography at discharge and follow-up LV function and volume assessment. RESULTS: Procalcitonin was associated with MACE on uni- and multivariable analysis. Kaplan-Meier assessment revealed an adverse outcome in subjects with procalcitonin above the median. Procalcitonin was related to markers of LV dysfunction and remodelling. CONCLUSION: Procalcitonin is associated with MACE, LV dysfunction and remodelling post-AMI.
BACKGROUND: Procalcitonin is involved in the inflammatory response and is associated with adverse prognosis in certain conditions. AIMS: To investigate the association between procalcitonin and major adverse cardiac events (MACE), left ventricular (LV) function and remodelling following acute myocardial infarction (AMI). METHODS: Plasma procalcitonin was measured in 977 patients with AMI. Subjects were followed for MACE (median 671 days). A subgroup underwent echocardiography at discharge and follow-up LV function and volume assessment. RESULTS: Procalcitonin was associated with MACE on uni- and multivariable analysis. Kaplan-Meier assessment revealed an adverse outcome in subjects with procalcitonin above the median. Procalcitonin was related to markers of LV dysfunction and remodelling. CONCLUSION: Procalcitonin is associated with MACE, LV dysfunction and remodelling post-AMI.
Authors: Martin Reindl; Christina Tiller; Magdalena Holzknecht; Ivan Lechner; Benjamin Henninger; Agnes Mayr; Christoph Brenner; Gert Klug; Axel Bauer; Bernhard Metzler; Sebastian J Reinstadler Journal: JAMA Netw Open Date: 2020-06-01